Healthcare Industry News: neurostimulator
News Release - September 9, 2009
St. Jude Medical Receives CE Mark Approval for World's Smallest, Longest-Lasting Rechargeable Deep Brain Stimulator for Parkinson's DiseaseFirst patient implanted with Brio neurostimulator at University of Cologne, Germany
ST. PAUL, Minn., Sept. 9--(HSMN NewsFeed)--St. Jude Medical, Inc. (NYSE:STJ ) today announced CE (Conformité Européenne) Mark approval of the Brio(TM) neurostimulator, the world’s smallest, longest-lasting rechargeable deep brain stimulation (DBS) device for treating the symptoms of Parkinson’s disease. A 67-year-old man who has suffered from Parkinson’s disease for more than 26 years became the first person to be implanted with the Brio neurostimulator.
Slightly larger than the typical man’s watch, the Brio neurostimulator has a thin 10 mm profile and weighs 29 grams (approximately 1 oz). Additionally, the device has the greatest recommended implant depth of any rechargeable DBS device. The thin profile and greater implant depth potentially makes the neurostimulator less noticeable and more comfortable for patients.
“Deep brain stimulation therapy is often the preferred treatment for many Parkinson’s disease patients,” said Professor Dr. Volker Sturm, chairman of neurosurgery at the University Hospital of Cologne. “For these patients, device size and longevity are important considerations. The small size of the Brio neurostimulator is a real improvement and was a good choice for this patient.”
The procedure was performed by Professor Sturm’s colleague, Dr. Mohammad Maarouf, at the University Hospital of Cologne.
The Brio DBS system delivers mild electrical pulses to specific targets in the brain, stimulating the structures that are involved in motor control. The system consists of a neurostimulator – a surgically implanted battery-operated device that generates the electrical pulses – and leads which carry the pulses to the brain to influence the irregular nerve signals responsible for the symptoms of Parkinson’s disease.
“The Brio neurostimulator is an important addition to our family of deep brain stimulation systems,” said Chris Chavez, president of the St. Jude Medical Neuromodulation Division. “We are excited to offer physicians a best-in-class product to help them meet the needs of patients who require a smaller, long-lasting rechargeable system in order to better control the symptoms of this debilitating disease.”
In addition to its small size, the Brio neurostimulator has the longest battery life of any rechargeable DBS device currently on the market with a 10-year battery longevity approval. For patients this means the device should provide sustainable therapy and maintain a reasonable recharge interval for at least 10 years of use at high settings. The device’s battery longevity may also maximize the time between device replacement procedures.
The Brio neurostimulator also features:
- Constant current circuitry that automatically adjusts to deliver consistent therapy over time.
- A dual header that accommodates two leads, allowing for bilateral stimulation from one device.
- High power capability, making it an appropriate choice for patients who require high energy settings to control their symptoms.
- A rechargeable battery that can be easily charged through a portable, wireless charging system, allowing patients the freedom to recharge comfortably while doing other activities.
Parkinson’s disease affects an estimated 6.3 million people worldwide, according to the European Parkinson’s Disease Association. The disease usually develops in people between the ages of 40 and 70, with an average age of onset of 60 years.
St. Jude Medical is also currently developing new DBS applications to address a growing list of neurological and psychiatric disorders. Clinical studies are underway in the U.S. for depression and essential tremor. For more information about these studies, visit www.BROADENstudy.com and www.PowerOverET.com.
About St. Jude Medical
St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. Headquartered in St. Paul, Minn., St. Jude Medical employs more than 15,000 people worldwide and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Quarterly Reports on Form 10-Q for the fiscal quarters ended April 4, 2009 and July 4, 2009. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Source: St. Jude Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.